- Home
- AKA vs NBTX Comparison
AKA vs NBTX Comparison
Compare AKA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- NBTX
- Stock Information
- Founded
- AKA 2018
- NBTX 2003
- Country
- AKA United States
- NBTX France
- Employees
- AKA N/A
- NBTX N/A
- Industry
- AKA Catalog/Specialty Distribution
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- NBTX Health Care
- Exchange
- AKA Nasdaq
- NBTX Nasdaq
- Market Cap
- AKA 251.5M
- NBTX 201.9M
- IPO Year
- AKA 2021
- NBTX 2020
- Fundamental
- Price
- AKA $21.01
- NBTX $3.38
- Analyst Decision
- AKA Buy
- NBTX Strong Buy
- Analyst Count
- AKA 4
- NBTX 1
- Target Price
- AKA $26.25
- NBTX $12.00
- AVG Volume (30 Days)
- AKA 7.7K
- NBTX 51.3K
- Earning Date
- AKA 11-07-2024
- NBTX 12-24-2024
- Dividend Yield
- AKA N/A
- NBTX N/A
- EPS Growth
- AKA N/A
- NBTX N/A
- EPS
- AKA N/A
- NBTX N/A
- Revenue
- AKA $564,586,000.00
- NBTX $45,220,186.00
- Revenue This Year
- AKA $5.44
- NBTX N/A
- Revenue Next Year
- AKA $4.25
- NBTX N/A
- P/E Ratio
- AKA N/A
- NBTX N/A
- Revenue Growth
- AKA 3.31
- NBTX 526.17
- 52 Week Low
- AKA $7.00
- NBTX $2.76
- 52 Week High
- AKA $33.73
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- AKA 48.73
- NBTX 45.16
- Support Level
- AKA $19.42
- NBTX $3.28
- Resistance Level
- AKA $21.53
- NBTX $3.69
- Average True Range (ATR)
- AKA 1.63
- NBTX 0.26
- MACD
- AKA 0.12
- NBTX 0.09
- Stochastic Oscillator
- AKA 49.96
- NBTX 66.67
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.